



FOR IMMEDIATE RELEASE

Contacts:

Company: Brian Hochheimer
The EMMES Corporation
301-251-1161, ext. 232
bhochheimer@emmes.com

Media: Karen Vahouny
703-624-2674
kvahouny@gmail.com

THE EMMES CORPORATION WINS IDIQ CONTRACT
New Contract Reflects Successful Strategy to Diversify Customer Base

Rockville, MD – March 17, 2014 –

The EMMES Corporation today announced that it has been awarded an indefinite delivery, indefinite quantity (IDIQ) contract to become part of a clinical studies network established by the Biomedical Advanced Research and Development Authority (BARDA) to perform studies needed to develop medical countermeasures against agents of bioterrorism, pandemic influenza, and other public health threats. BARDA is part of the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response.

The goal of the Medical Countermeasure Clinical Studies Network is to generate clinical trial data that will evaluate medical countermeasures, such as vaccines, therapeutics, diagnostics and medical devices. These countermeasures would address a range of potential threats, including chemical, biological, radiological, nuclear, pandemic influenza, and emerging infectious diseases.

Under the contract, EMMES will provide a full range of services that support public health emergency preparedness. These include statistical expertise and project management, study design and protocol development, data collection, and data analysis and reporting. In addition, the company will also provide enhanced safety reporting through its pharmacovigilance program with both Emergency Medicine and Infectious Disease expertise and will manage a large team of subcontractors at laboratories and sites across the country. The two-year contract, which includes three one-year options, has a ceiling of \$100 million. EMMES was one of five companies selected to compete for services under this IDIQ contract.

According to Dr. Anne Lindblad, president and chief executive officer, "We are so pleased to have the opportunity to support the BARDA Medical Countermeasure Clinical Studies Network. EMMES has a

long history of public health research and a wealth of experience in the prevention and treatment of influenza and infectious disease. We are proud to contribute our expertise to this important effort.”

She added, “This is a new client agency for EMMES and represents another important opportunity within the Department of Health and Human Services.”

About The EMMES Corporation

EMMES is a professional partner to clinicians, scientists, and program leaders around the world. Founded in 1977, the company provides scientific and technical support for clinical research studies funded by industry, foundations and government agencies. EMMES has more than 400 employees whose specialties range from biostatistics and bioinformatics to safety surveillance and monitoring to data management and information technology. Its staff is committed to the highest quality of research, evidenced by numerous major scientific publications and presentations. In addition to its headquarters in Rockville, MD, the company has offices in Canada and India. For more information, visit www.emmes.com.